Going-concern and liquidity shortfall
The company states its cash is not expected to support working capital needs for 12 months.
- Scope
- Corporate funding and ongoing R&D operations
- Materiality
- high
Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for serious and chronic viral diseases. Its programs use structure-based drug design to advance small-molecule candidates for influenza, coronavirus, norovirus, and hepatitis C, but the company does not yet have approved products or recurring product revenue.
3.68
3.68
| % | |
|---|---|
| Clinical-stage antiviral candidates | 70% Small-molecule drug candidates in preclinical and clinical development for viral diseases. |
| Discovery platform and research programs | 20% Structure-based technologies used to identify and optimize novel antiviral compounds. |
| Partnering and collaboration opportunities | 10% Out-licensing or strategic collaboration potential for programs after early clinical work. |
Cocrystal does not sell commercial products today; its economic counterparties are primarily investors, clinical...
- Equity investorsprimary
Provide capital through public and private offerings to fund R&D and operations.
- Strategic pharmaceutical partnerssecondary
May license or co-develop antiviral candidates after clinical de-risking.
- Clinical research organizationssecondary
Buy trial management and development services to execute studies efficiently.
- Future healthcare buyersemerging
Hospitals, physicians, and payers would buy approved antivirals if programs reach market.
The company is headquartered in the United States and appears to run a U.S.-centric corporate and financing model, with...
- •United States is the corporate base and main financing market
- •Clinical development may involve non-U.S. trial and regulatory activity
- •MHRA references indicate UK regulatory interaction for study amendments
- •No commercial revenue geography is disclosed because products are not sold
- •Geographic exposure is mainly operational and regulatory, not sales-driven
Cocrystal’s strategy is to advance a focused antiviral pipeline through early clinical proof-of-concept while...
01
Advance lead antiviral candidates through clinical developmentshort-term
Clinical data are needed to validate efficacy, safety, and partnering value.
02
Secure strategic partnershipsmedium-term
Partnerships can provide non-dilutive funding and external development capability.
03
Preserve liquidity and access capital marketsshort-term
The company has no ongoing product revenue and depends on external financing.
The company faces substantial going-concern and financing risk because it has no approved products, no recurring...
Clinical trial execution risk
The influenza Phase 2a study faced low infection rates, limiting data analysis.
- Scope
- CC-42344 and other pipeline programs
- Materiality
- high
Financing dilution risk
Future funding is expected to come from equity or partner transactions that may dilute holders.
- Scope
- ATM facility and future capital raises
- Materiality
- high
Regulatory and development delay risk
Protocol amendments or resubmissions may be needed before additional enrollment can proceed.
- Scope
- MHRA-related study actions and clinical timelines
- Materiality
- medium
Inflation and tariff cost pressure
Higher operating and trial costs could stress limited working capital.
- Scope
- R&D and general corporate spending
- Materiality
- medium
Research and development expense recognition
Drives quarterly loss volatility and reflects pipeline progress
Going-concern assessment
Important for liquidity analysis and valuation
Warrant liability accounting
Can create non-cash fair value changes in earnings
Accounting estimates and assumptions
Can materially affect reported expenses and balance-sheet items
CUMBERLAND PHARMACEUTICALS INC
CPIX · Pharmaceutical Preparations
Camurus
CAMX.ST · Health Care
Camurus is an international biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases.
CYTOKINETICS INC
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Swedish Orphan Biovitrum
SOBI.ST · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Phathom Pharmaceuticals, Inc.
PHAT · Pharmaceutical Preparations
Phathom Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing vonoprazan-based therapies for acid-related gastrointestinal diseases.
BIOCRYST PHARMACEUTICALS INC
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
: 28.4.2026